<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Jun H</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>&lt;i>Plasmodium falciparum&lt;/i> is the most lethal malaria parasite. Recent phase 1b vaccine trials using &lt;i>P. falciparum&lt;/i> reticulocyte binding protein homolog 5 (PfRh5) demonstrated safety and promising efficacy in preventing merozoite invasion. PfRh5 has emerged as a strong vaccine candidate due to its essential role in merozoite invasion and limited sequence variation. For effective malaria vaccine development, especially in high-transmission settings, strain-transcending activity must be considered. Ongoing monitoring of antigenic variation and natural immune responses is important to estimate vaccine efficacy across geographically diverse populations.&lt;h4>Methods&lt;/h4>Samples for this study were collected from four villages in each of the Kigoma and Geita regions, kn</pubmed_abstract><journal>Frontiers in immunology</journal><pagination>1495513</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11609159</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Estimation of PfRh5-based vaccine efficacy in asymptomatic &lt;i>Plasmodium falciparum&lt;/i> patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening.</pubmed_title><pmcid>PMC11609159</pmcid><pubmed_authors>Hong M</pubmed_authors><pubmed_authors>Jun H</pubmed_authors><pubmed_authors>Na S</pubmed_authors><pubmed_authors>Park WS</pubmed_authors><pubmed_authors>Lee SJ</pubmed_authors><pubmed_authors>Todd J</pubmed_authors><pubmed_authors>Lee WJ</pubmed_authors><pubmed_authors>Lu F</pubmed_authors><pubmed_authors>Kidima W</pubmed_authors><pubmed_authors>Mazigo E</pubmed_authors><pubmed_authors>Han JH</pubmed_authors><pubmed_authors>Chun W</pubmed_authors><pubmed_authors>Kwon B</pubmed_authors><pubmed_authors>Muh F</pubmed_authors><pubmed_authors>Louis JM</pubmed_authors><pubmed_authors>Lee SU</pubmed_authors><pubmed_authors>Manjurano A</pubmed_authors><pubmed_authors>Heo J</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Syahada JH</pubmed_authors><pubmed_authors>Kwon TH</pubmed_authors><pubmed_authors>Han ET</pubmed_authors><pubmed_authors>Fitriana F</pubmed_authors><pubmed_authors>Ahmed MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Estimation of PfRh5-based vaccine efficacy in asymptomatic &lt;i>Plasmodium falciparum&lt;/i> patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening.</name><description>&lt;h4>Background&lt;/h4>&lt;i>Plasmodium falciparum&lt;/i> is the most lethal malaria parasite. Recent phase 1b vaccine trials using &lt;i>P. falciparum&lt;/i> reticulocyte binding protein homolog 5 (PfRh5) demonstrated safety and promising efficacy in preventing merozoite invasion. PfRh5 has emerged as a strong vaccine candidate due to its essential role in merozoite invasion and limited sequence variation. For effective malaria vaccine development, especially in high-transmission settings, strain-transcending activity must be considered. Ongoing monitoring of antigenic variation and natural immune responses is important to estimate vaccine efficacy across geographically diverse populations.&lt;h4>Methods&lt;/h4>Samples for this study were collected from four villages in each of the Kigoma and Geita regions, kn</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-01T12:41:53.334Z</modification><creation>2025-04-04T01:20:59.146Z</creation></dates><accession>S-EPMC11609159</accession><cross_references><pubmed>39624090</pubmed><doi>10.3389/fimmu.2024.1495513</doi></cross_references></HashMap>